Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis, Pharmacokinetics”

127 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 127 results

Early research (Phase 1)Study completedNCT03520517
What this trial is testing

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

Who this might be right for
Amyotrophic Lateral SclerosisALSLou Gehrig Disease+3 more
Biohaven Pharmaceuticals, Inc. 22
Early research (Phase 1)Active Not RecruitingNCT07597668
What this trial is testing

A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations

Who this might be right for
Multiple Sclerosis
R-Pharm 180
Large-scale testing (Phase 3)Looking for participantsNCT07325292
What this trial is testing

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Sanofi 160
Early research (Phase 1)Study completedNCT05853835
What this trial is testing

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

Who this might be right for
Autoimmune DiseasesMultiple Sclerosis
LAPIX Therapeutics Inc. 72
Very early researchLooking for participantsNCT07337785
What this trial is testing

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Who this might be right for
Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Tongji Hospital 36
Testing effectiveness (Phase 2)Study completedNCT00489489
What this trial is testing

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Sanofi 118
Early research (Phase 1)Study completedNCT00676156
What this trial is testing

The Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Oregon Health and Science University 40
Testing effectiveness (Phase 2)Study completedNCT01517282
What this trial is testing

Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
MorphoSys AG 32
Early research (Phase 1)Study completedNCT02641041
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants

Who this might be right for
Central Nervous System (CNS) Demyelinating DiseaseMultiple Sclerosis
Biogen 24
Large-scale testing (Phase 3)Study completedNCT01462318
What this trial is testing

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 133
Early research (Phase 1)Study completedNCT02797015
What this trial is testing

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

Who this might be right for
Multiple Sclerosis
Celgene 22
Early research (Phase 1)Study completedNCT00559702
What this trial is testing

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Who this might be right for
Relapsing-Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
Biogen 76
Early research (Phase 1)Study completedNCT06106074
What this trial is testing

Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants

Who this might be right for
Multiple Sclerosis
Sanofi 71
Early research (Phase 1)Ended earlyNCT01435993
What this trial is testing

Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GlaxoSmithKline 3
Early research (Phase 1)Active Not RecruitingNCT05704361
What this trial is testing

Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Hoffmann-La Roche 119
Testing effectiveness (Phase 2)Study completedNCT02782858
What this trial is testing

Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GeNeuro SA 270
Large-scale testing (Phase 3)Active Not RecruitingNCT06869785
What this trial is testing

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Who this might be right for
Relapsing Multiple Sclerosis (RMS)
Novartis Pharmaceuticals 196
Testing effectiveness (Phase 2)Study completedNCT02442570
What this trial is testing

Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Delta Crystallon BV 32
Large-scale testing (Phase 3)Looking for participantsNCT05877963
What this trial is testing

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Who this might be right for
Relapsing Multiple Sclerosis
TG Therapeutics, Inc. 800
Testing effectiveness (Phase 2)Study completedNCT02542787
What this trial is testing

Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis

Who this might be right for
Spasticity in People With Multiple Sclerosis
Canbex Therapeutics Ltd 160
Next Page